Evidence map›Paper›PMID 42351184›Full record

ArticleMolecular neurodegeneration2026

Standardized protocol to detect phosphorylated α-synuclein in skin biopsies: recommendations from an expert panel.

V Donadio, C Gibbons, C Delprete, K Doppler, A Furia, A Incensi, M Ingelsson, J Yang, M Liu, G Melli and 6 more

Abstract readConsensus Statement
In one paragraph

Article in Molecular neurodegeneration, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

V Donadio *IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, via Altura 3, 40139, Bologna, Italy. vincenzo.donadio@unibo.it.
C Gibbons *Department of Neurology, Beth Israel Deaconess Medical Center Boston, Boston, USA.
C DelpreteIRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, via Altura 3, 40139, Bologna, Italy.
K DopplerDepartment of Neurology, University Hospital Würzburg, Würzburg, Germany.
A FuriaIRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, via Altura 3, 40139, Bologna, Italy.
A IncensiIRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, via Altura 3, 40139, Bologna, Italy.
M IngelssonDepartment of Public Health and Caring Sciences, Geriatrics, Uppsala University, Uppsala, Sweden.
J YangDepartment of Neurology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
M LiuDepartment of Neurology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
G MelliInstitute for Translational Research (IRT), Faculty of Biomedical Sciences, Università della Svizzera italiana (USI) and Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.
M NolanoDepartment of Neurosciences, Reproductive Sciences and Odontostomatology, University Federico Il of Naples, Naples, Italy.
V ProviteraNeurology Department, Skin Biopsy Laboratory, Istituti Clinici Scientifici Maugeri IRCCS, Telese Terme, Italy.
G RizzoIRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, via Altura 3, 40139, Bologna, Italy.
K TsukitaDepartment of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
R Freeman *Department of Neurology, Beth Israel Deaconess Medical Center Boston, Boston, USA.
R Liguori *IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, via Altura 3, 40139, Bologna, Italy.

Funding

Ministero della salute RF-2021- 12374029Ministero della Salute RF-2021- 12374029
6 · The paper itself

Abstract

backgroundSkin biopsy is a promising diagnostic tool for the in vivo identification of Parkinson's disease and other α-synucleinopathies. However, despite increasing adoption, methodological variability exists among different laboratories applying this technique. To move toward a formal standardized protocol, leading experts in the field convened for a meeting focused on discussing and harmonizing the main methodological differences. The outcome of this meeting was a consensus-based skin biopsy protocol, which is here presented.

resultsA formal expert opinion conference was held on November 15-16, 2024, at the IRCCS Institute of Neurological Sciences of Bologna (Italy). The consensus was reached by using a Question & Answer format following the PICO (Population, Intervention, Comparison, Outcome) methodology. An online Delphi survey was then performed based on the contrasting issues raised during the meeting. Unanimous consensus was reached on key elements, including the skin biopsy technique, choice of fixative, use of a cryostat, staining method for phosphorylated α-synuclein (p-α-syn), use of high-power fluorescence microscope, co-localization of p-α-syn with neuronal or glial markers, and high-magnification analysis. Additional agreement, achieved through the Delphi method, concerned specific procedural parameters such as the number of samples and section thickness, punch diameter, preferred biopsy sites in cases of asymmetric motor involvement, quantitative methods for assessing p-α-syn load, and use of p-α-syn as the optimal marker for identifying misfolded α-synuclein in the skin. Conclusions We have developed a consensus-based protocol for the detection of p-α-syn in skin samples from patients with suspected α-synucleinopathies, with the aim of promoting standardization, a broader adoption of the method, and its translation into clinical practice.

Indexed as

alpha-SynucleinParkinson DiseaseSkinSynucleinopathiesBiopsyHumansPhosphorylationalpha-SynucleinBiomarkerExpert panelPhosphorylated α-synuclein at ser129Skin biopsyStandardization

Identifiers

PMID42351184
PMCPMC13560214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.